The risk of obstetric complications such as miscarriage, preterm delivery, intrauterine growth retardation, and pre-eclampsia is significantly higher in patients with SLE than in normal women, and SLE patients who become pregnant need to be followed up by both internal medicine and obstetrics and gynecology. If the disease is active during pregnancy, the decision to terminate the pregnancy should be made on a case-by-case basis. Monitoring of disease activity and treatment of active disease in both symptomatic and asymptomatic patients should be performed in female patients with lupus who have a combined pregnancy. Mothers should be evaluated for disease activity at least every three months, or more frequently if the disease is active. Monitoring includes physical examination, including blood pressure, renal function, urinalysis, blood creatinine concentration, 24-hour urine protein quantification, complete blood count, anti-ds-DNA antibody titer, complement C4/C3 levels, and pelvic ultrasound to monitor fetal growth, anti-Ro/SSA antibodies, anti-La/SSB antibodies, and antiphospholipid antibodies (at the onset of pregnancy).